At 270 pounds, Serna decided to try Zepbound, one of several weight-loss medications for those struggling with obesity.

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...